Nectar Lifesciences Limited reported earnings results for the fourth quarter and full year ended March 31, 2023. For the fourth quarter, the company reported sales was INR 4,460.23 million compared to INR 5,474.29 million a year ago. Revenue was INR 4,067.39 million compared to INR 4,767.53 million a year ago. Net income was INR 36.77 million compared to INR 116.6 million a year ago. Basic earnings per share from continuing operations was INR 0.16 compared to INR 0.52 a year ago. Diluted earnings per share from continuing operations was INR 0.16 compared to INR 0.52 a year ago.
For the full year, sales was INR 17,465.57 million compared to INR 19,255.23 million a year ago. Revenue was INR 15,668.48 million compared to INR 16,801.5 million a year ago. Net loss was INR 241.83 million compared to net income of INR 250.47 million a year ago. Basic loss per share from continuing operations was INR 1.08 compared to basic earnings per share from continuing operations of INR 1.12 a year ago. Diluted loss per share from continuing operations was INR 1.08 compared to diluted earnings per share from continuing operations of INR 1.12 a year ago.